insights_auto
Why is AGIO up 3.34%?
Dive Deeperchevron_right
AGIO:NASDAQ
Agios Pharmaceuticals Inc
$32.82
arrow_upward
+3.34%(+1.06) 1D
$33.00
arrow_upward
+0.55% (+0.18)bedtimeAfter hours
Closed: Nov 11, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Open
$31.99
High
$33.12
Low
$31.53
Mkt. cap
1.96B
Avg. vol.
1.31M
Volume
0.00
52-wk high
$45.99
52-wk low
$22.24
EPS
-$6.32
Beta
0.66
Shares outstanding
59.81M
No. of employees
540
Open
$31.99
High
$33.12
Low
$31.53
Mkt. cap
1.96B
Avg. vol.
1.31M
Volume
0.00
52-wk high
$45.99
52-wk low
$22.24
EPS
-$6.32
Beta
0.66
Shares outstanding
59.81M
No. of employees
540
News stories
From web sources and news partners
TradingView
·
3 days ago
Weekly Recap: Q3 product revenue rises and FDA delays mitapivat review
Yahoo Finance
·
5 days ago
Agios Pharmaceuticals (AGIO) Stock Looks Pricey Despite Its 39% Run
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc